Adverse effects of antiretroviral therapy in pregnant women infected with HIV in Brazil from 2000 to 2015: a cohort study

Table 4 Comparative analysis between pregnant women in use of NNRTI and PI

	NNRTI		PI		p*	RR	CI 95%
	n	%	n	%	p*	RR	CI 95%
Co-infections during pregnacy					0.010
Yes	111	78.2	515	86.7		0.60	0.44–0.81
No	31	21.8	79	13.3		1.00
Obstetrical complications					0.001
Yes	57	40.1	334	56.0		0.60	0.44–0.81
No	85	59.9	262	44.0		1.00
ART adherence during pregnancy					0.387
Yes	121	86.4	494	83.4		1.21	0.78–1.88
No	19	13.6	98	16.6		1.00
ART changes during pregnancy					< 0.0001
Yes	10	7.1	134	22.5		0.31	0.17–0.58
No	131	92.9	462	77.5		1
Viral load after ART					0.001
Undetectable	57	47.5	365	63.4		1
Detectable	63	52.5	211	36.6		1.70	1.23–2.35
Anemia					0.664
Yes	73	58.4	323	56.3		1.07	0.78–1.48
No	52	41.6	251	43.7		1
Thrombocytopenia					0.479
Yes	15	12.1	83	14.5		0.08	0.51–1.38
No	109	87.9	488	85.5		1
Hepatic alteration					< 0.0001
Yes	94	83.2	267	47.8		4.26	2.67–6.81
No	19	16.8	292	52.2		1
Dyslipidemia					0.015
Yes	52	72.2	406	83.9		0.56	0.35–0.89
No	20	27.8	78	16.1		1
Allergic reaction					0.002
Yes	10	7.5	11	1.9		2.71	1.69–4.37
No	123	92.5	578	98.1		1
Fasting glycemia alteration					0.032
Yes	12	11.9	112	21.1		0.55	0.31–0.97
No	89	88.1	418	78.9		1
Total	142	100	597	100

(#) Numbers are different due to the lack of information on some patients
* Chi-square
ART antiretroviral therapy, NNRTI non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor

ISSN: 1471-2334